<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01325311</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2013-00451</org_study_id>
    <secondary_id>NCI-2013-00451</secondary_id>
    <secondary_id>UWI09-14-01</secondary_id>
    <secondary_id>CDR0000698228</secondary_id>
    <secondary_id>CO-10805</secondary_id>
    <secondary_id>CO 10805</secondary_id>
    <secondary_id>UWI09-14-01</secondary_id>
    <secondary_id>N01CN35153</secondary_id>
    <secondary_id>P30CA014520</secondary_id>
    <nct_id>NCT01325311</nct_id>
  </id_info>
  <brief_title>Cholecalciferol and Genistein Before Surgery in Treating Patients With Early Stage Prostate Cancer</brief_title>
  <official_title>Phase IIA, Randomized Placebo-Controlled Trial of Single High Dose Cholecalciferol and Daily Genistein (G-2535) Versus Placebo in Men With Early Stage Prostate Cancer Undergoing Prostatectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase II trial studies cholecalciferol and genistein compared to placebo in
      treating patients with early stage prostate cancer. Cholecalciferol and genistein may slow
      the growth of cancer cells and may be an effective treatment for prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine differences in prostate tissue steady state concentrations of calcitriol in
      participants treated with a single dose cholecalciferol (200,000 IU) and G-2535 (which
      provides 600 mg of genistein) and those receiving placebo.

      SECONDARY OBJECTIVES:

      I. To determine the effect of each intervention arm and resulting prostate tissue levels of
      calcitriol on down-stream related biomarkers and related mechanistic pathways in blood and
      tissue.

      OUTLINE: Patients are randomized to 1 of 2 treatment arms.

      ARM I: Patients receive cholecalciferol orally (PO) on day 1 and genistein PO once daily (QD)
      on days 1-21 or 1-28. Patients then undergo prostatectomy.

      ARM II: Patients receive placebo PO on day 1 and placebo PO QD on days 1-21 or 1-28. Patients
      then undergo prostatectomy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tissue Levels of Calcitriol Between the Placebo and Cholecalciferol/Genistein Arms</measure>
    <time_frame>up to Day 35</time_frame>
    <description>This is a measure of calcitriol in prostate tissue comparing placebo and cholecalciferol/genistein</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Detectability of Calcitriol Levels in Tissue Between the Placebo and Cholecalciferol/Genistein Arms</measure>
    <time_frame>up to 35 days</time_frame>
    <description>To identify the amount of Calcitriol that is found in the tissue comparing Placebo and Cholecalciferol/Genistein</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Levels of Calcidiol in the Participants Serum</measure>
    <time_frame>Baseline and up to day 35</time_frame>
    <description>This is measuring the amount of Calcidiol that was found in the participants blood Serum at baseline and end of study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of Calcitriol in Participants Serum</measure>
    <time_frame>baseline and Up to Day 35</time_frame>
    <description>This is measuring the amount of Calcitriol that was found in the participants blood Serum at baseline and end of study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PBMC CYP mRNA Expression of CYP24</measure>
    <time_frame>Baseline and Up to Day 35</time_frame>
    <description>This is a measure of expression of CYP24 in comparing placebo to Cholecalciferol/genistein.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PBMC CYP mRNA Expression of CYP27B1</measure>
    <time_frame>Up to Day 35</time_frame>
    <description>This is a measure of expression of CYP27B1 in comparing placebo to Cholecalciferol/genistein.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total PSA in Serum</measure>
    <time_frame>at Baseline and up to Day 35</time_frame>
    <description>This is a measure of the concentration of PSA in the blood serum at baseline and at the end of study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Calcium Levels at Baseline and Pre-Surgery</measure>
    <time_frame>Baseline and Day 35</time_frame>
    <description>This is a measurement of calcium in the Blood serum at baseline and at the end of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total IGF-1 in Serum at Baseline and Pre-Surgery</measure>
    <time_frame>Baseline and up to Day 35</time_frame>
    <description>This is measuring the concentration of the Biomarker IGF-1 in blood serum at Baseline and at the end of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total IGF-2 in Serum at Baseline and Pre-Surgery</measure>
    <time_frame>Baseline and Up to Day 35</time_frame>
    <description>This is measuring the concentration of the Biomarker IGF-2 in blood serum at Baseline and at the end of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total IGFBP-3 in Serum at Baseline and Pre-Surgery</measure>
    <time_frame>Baseline and Up to Day 35</time_frame>
    <description>This is measuring the concentration of the Biomarker IGFBP-3 in blood serum at Baseline and at the end of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total PTH in Serum at Baseline and Pre-Surgery</measure>
    <time_frame>Baseline and Up to Day 35</time_frame>
    <description>This is measuring the concentration of the Biomarker PTH in blood serum at Baseline and at the end of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunohistochemistry Measurements in Benign Prostate Tissue (BPT)</measure>
    <time_frame>Up to Day 35</time_frame>
    <description>The Immunohistochemistry measurement for: AR (Nucleus), VDR (Cytoplasm), p21 (Nucleus), PGE2 (Cytoplasm), TUNEL Pos (Nucleus), Caspase 3 (Cytoplasm), PSMA (Cytoplasm), IGF-1 and IGF-2 (Cytoplasm), Akt (Nucleus and Cytoplasm), and pAkt (nucleus and Cytoplasm)
This is to serve as normalized control data to determine expression of protein.
The normalized optical densities were measured as optical density per unit area by densitometric scanning using Vectra imaging system (Perkin Elmer).
This Optical Density is based on fluorescence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunohistochemistry Measurements in Prostate Cancer Tissue (PCA)</measure>
    <time_frame>Up to day Day 35</time_frame>
    <description>The Immunohistochemistry measurement for: AR (Nucleus), VDR (Cytoplasm), p21 (Nucleus), PGE2 (Cytoplasm), TUNEL Pos (Nucleus), Caspase 3 (Cytoplasm), PSMA (Cytoplasm), IGF-1 and IGF-2 (Cytoplasm), Akt (Nucleus and Cytoplasm), and pAkt (nucleus and Cytoplasm)
This is to serve as normalized case data to determine expression of protein.
The normalized optical densities were measured as optical density per unit area by densitometric scanning using Vectra imaging system (Perkin Elmer).
This Optical Density is based on fluorescence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants With CYP24 and CYP27B1 SNPs (DNA From Paxgene)</measure>
    <time_frame>up to Day 35</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Prostate Adenocarcinoma</condition>
  <condition>Stage I Prostate Cancer</condition>
  <condition>Stage IIA Prostate Cancer</condition>
  <condition>Stage IIB Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I (cholecalciferol, genistein)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive cholecalciferol PO on day 1 and genistein PO QD on days 1-21 or 1-28. Patients then undergo prostatectomy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive placebo PO on day 1 and placebo PO QD on days 1-21 or 1-28. Patients then undergo prostatectomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholecalciferol</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (cholecalciferol, genistein)</arm_group_label>
    <other_name>9,10-Secocholesta-5,7,10(19)-trien-3-ol</other_name>
    <other_name>Calciol</other_name>
    <other_name>Delsterol</other_name>
    <other_name>Vitamin D3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Genistein</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (cholecalciferol, genistein)</arm_group_label>
    <other_name>4',5, 7-Trihydroxyisoflavone</other_name>
    <other_name>Genestein</other_name>
    <other_name>Genisteol</other_name>
    <other_name>Prunetol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (cholecalciferol, genistein)</arm_group_label>
    <arm_group_label>Arm II (placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacological Study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (cholecalciferol, genistein)</arm_group_label>
    <arm_group_label>Arm II (placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm II (placebo)</arm_group_label>
    <other_name>placebo therapy</other_name>
    <other_name>PLCB</other_name>
    <other_name>sham therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants must have microscopic confirmation of adenocarcinoma of the prostate
             within three months of randomization; clinical stage T1 and T2 a, b, or c are allowed

          -  Participants' prostate cancer must be confined to the prostate (in the clinical
             judgment of the treating physician)

          -  Participants must be candidates for prostatectomy

          -  Participants must have Eastern Cooperative Oncology Group (ECOG) performance status
             =&lt;1 (Karnofsky &gt;= 70%)

          -  White blood cell (WBC) within normal limits

          -  Platelets &gt;= 100 K/uL

          -  Hemoglobin &gt;= 10 g/dL

          -  Thyroid-stimulating hormone (TSH) =&lt; 4.20 uIU/mL

          -  Free T4 =&lt; 12.5 ng/dL

          -  Bilirubin within upper limit of normal

          -  Aspartate aminotransferase (AST) =&lt; 1.5 x upper limit of normal

          -  Creatinine =&lt; 2.0 mg/dL

          -  Serum calcium: within institutional normal limits

          -  Participants must agree to stop taking nonsteroidal anti-inflammatory drugs (NSAIDS)
             during the course of the study, however, low dose aspirin (&lt; 100 mg/day) will be
             allowed; no wash out period is required

          -  Participants must be willing to discontinue consuming soy products and ingesting
             vitamin supplements while participating in this study

          -  The effects of cholecalciferol and genistein on the developing human fetus at the
             recommended therapeutic doses are unknown; for this reason, participants must agree to
             use adequate contraception (hormonal or barrier method of birth control; abstinence)
             for the duration of study participation

          -  Participants must have the ability to understand and sign a consent form indicating
             the investigational nature of the treatment and its potential risks

        Exclusion Criteria:

          -  Participants may not have received any prior therapy for prostate cancer including:
             chemotherapy, hormonal therapy, brachytherapy, or external radiation

          -  Participants may not be receiving concurrent systemic therapy for other cancers

          -  Participants may not be receiving any other investigational agents

          -  Participants may not be taking the following p450 inducers and inhibitors:
             carbamazepine, clarithromycin, fluconazole, fosphenytoin, itraconazole, ketoconazole,
             phenobarbital, phenytoin, rifabutin, rifampin

          -  Participants who took finasteride or dutasteride within 6 months of the
             pre-randomization biopsy, are currently taking finasteride or dutasteride, or are
             planning on taking these agents during study participation

          -  Participants with a history of allergic reactions attributed to genistein or placebo,
             or compounds of similar chemical or biologic composition

          -  Participants with uncontrolled intercurrent illness including, but not limited to
             ongoing or active infection, symptomatic congestive heart failure, unstable angina
             pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would
             limit compliance with study requirements

          -  Participants requires thyroid replacement therapy; Note: participants with a history
             of thyroid disease &gt; 5 years ago, with current normal thyroid function, will be
             considered eligible

          -  Participant has current, known nephrolithiasis or a history of nephrolithiasis within
             the past 5 years

          -  Participant has any history of sarcoidosis
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Jarrard</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University/Sidney Kimmel Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lahey Hospital and Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minneapolis Veterans Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Medical Center-Fairview</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Urologic Research Center</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29572</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology San Antonio Research PA</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2011</study_first_submitted>
  <study_first_submitted_qc>March 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2011</study_first_posted>
  <results_first_submitted>December 24, 2015</results_first_submitted>
  <results_first_submitted_qc>June 20, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 3, 2016</results_first_posted>
  <last_update_submitted>June 20, 2016</last_update_submitted>
  <last_update_submitted_qc>June 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Genistein</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm II (Placebo)</title>
          <description>Patients receive placebo PO on day 1 and placebo PO QD on days 1-21 or 1-28. Patients then undergo prostatectomy.
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies
Placebo: Given PO</description>
        </group>
        <group group_id="P2">
          <title>Arm I (Cholecalciferol, Genistein)</title>
          <description>Patients receive cholecalciferol PO on day 1 and genistein PO QD on days 1-21 or 1-28. Patients then undergo prostatectomy.
Cholecalciferol: Given PO
Genistein: Given PO
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm II (Placebo)</title>
          <description>Patients receive placebo PO on day 1 and placebo PO QD on days 1-21 or 1-28. Patients then undergo prostatectomy.
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies
Placebo: Given PO</description>
        </group>
        <group group_id="B2">
          <title>Arm I (Cholecalciferol, Genistein)</title>
          <description>Patients receive cholecalciferol PO on day 1 and genistein PO QD on days 1-21 or 1-28. Patients then undergo prostatectomy.
Cholecalciferol: Given PO
Genistein: Given PO
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.75" spread="4.50"/>
                    <measurement group_id="B2" value="62.14" spread="4.26"/>
                    <measurement group_id="B3" value="61.40" spread="4.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Tissue Levels of Calcitriol Between the Placebo and Cholecalciferol/Genistein Arms</title>
        <description>This is a measure of calcitriol in prostate tissue comparing placebo and cholecalciferol/genistein</description>
        <time_frame>up to Day 35</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm II (Placebo)</title>
            <description>Patients receive placebo PO on day 1 and placebo PO QD on days 1-21 or 1-28. Patients then undergo prostatectomy.
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies
Placebo: Given PO</description>
          </group>
          <group group_id="O2">
            <title>Arm I (Cholecalciferol, Genistein)</title>
            <description>Patients receive cholecalciferol PO on day 1 and genistein PO QD on days 1-21 or 1-28. Patients then undergo prostatectomy.
Cholecalciferol: Given PO
Genistein: Given PO
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Tissue Levels of Calcitriol Between the Placebo and Cholecalciferol/Genistein Arms</title>
          <description>This is a measure of calcitriol in prostate tissue comparing placebo and cholecalciferol/genistein</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.045" spread="0.127"/>
                    <measurement group_id="O2" value="0.057" spread="0.150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Using the Student t-test. If the normality assumption is tenuous, an appropriate transformation of the data such as logarithm will be considered for Student t-test or a nonparametric test such as Wilcoxon rank-sum test will be used for comparison.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.922</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Levels of Calcidiol in the Participants Serum</title>
        <description>This is measuring the amount of Calcidiol that was found in the participants blood Serum at baseline and end of study</description>
        <time_frame>Baseline and up to day 35</time_frame>
        <population>Due to sample one participant in Arm 1 was not analyzed for this Outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm II (Placebo)</title>
            <description>Patients receive placebo PO on day 1 and placebo PO QD on days 1-21 or 1-28. Patients then undergo prostatectomy.
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies
Placebo: Given PO</description>
          </group>
          <group group_id="O2">
            <title>Arm I (Cholecalciferol, Genistein)</title>
            <description>Patients receive cholecalciferol PO on day 1 and genistein PO QD on days 1-21 or 1-28. Patients then undergo prostatectomy.
Cholecalciferol: Given PO
Genistein: Given PO
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Levels of Calcidiol in the Participants Serum</title>
          <description>This is measuring the amount of Calcidiol that was found in the participants blood Serum at baseline and end of study</description>
          <population>Due to sample one participant in Arm 1 was not analyzed for this Outcome.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.5" spread="5.5"/>
                    <measurement group_id="O2" value="24.5" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-Surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.2" spread="5.1"/>
                    <measurement group_id="O2" value="27.3" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Detectability of Calcitriol Levels in Tissue Between the Placebo and Cholecalciferol/Genistein Arms</title>
        <description>To identify the amount of Calcitriol that is found in the tissue comparing Placebo and Cholecalciferol/Genistein</description>
        <time_frame>up to 35 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm II (Placebo)</title>
            <description>Patients receive placebo PO on day 1 and placebo PO QD on days 1-21 or 1-28. Patients then undergo prostatectomy.
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies
Placebo: Given PO</description>
          </group>
          <group group_id="O2">
            <title>Arm I (Cholecalciferol, Genistein)</title>
            <description>Patients receive cholecalciferol PO on day 1 and genistein PO QD on days 1-21 or 1-28. Patients then undergo prostatectomy.
Cholecalciferol: Given PO
Genistein: Given PO
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Detectability of Calcitriol Levels in Tissue Between the Placebo and Cholecalciferol/Genistein Arms</title>
          <description>To identify the amount of Calcitriol that is found in the tissue comparing Placebo and Cholecalciferol/Genistein</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Undetectable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Detectable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Levels of Calcitriol in Participants Serum</title>
        <description>This is measuring the amount of Calcitriol that was found in the participants blood Serum at baseline and end of study.</description>
        <time_frame>baseline and Up to Day 35</time_frame>
        <population>Due to sample one participant in Arm 1 was not analyzed for this Outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm II (Placebo)</title>
            <description>Patients receive placebo PO on day 1 and placebo PO QD on days 1-21 or 1-28. Patients then undergo prostatectomy.
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies
Placebo: Given PO</description>
          </group>
          <group group_id="O2">
            <title>Arm I (Cholecalciferol, Genistein)</title>
            <description>Patients receive cholecalciferol PO on day 1 and genistein PO QD on days 1-21 or 1-28. Patients then undergo prostatectomy.
Cholecalciferol: Given PO
Genistein: Given PO
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Levels of Calcitriol in Participants Serum</title>
          <description>This is measuring the amount of Calcitriol that was found in the participants blood Serum at baseline and end of study.</description>
          <population>Due to sample one participant in Arm 1 was not analyzed for this Outcome.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.1"/>
                    <measurement group_id="O2" value="0.5" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-Surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.7"/>
                    <measurement group_id="O2" value="0.1" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PBMC CYP mRNA Expression of CYP24</title>
        <description>This is a measure of expression of CYP24 in comparing placebo to Cholecalciferol/genistein.</description>
        <time_frame>Baseline and Up to Day 35</time_frame>
        <population>Due to sample two participant in Arm I and 2 participants in Arm II were not analyzed for this Outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm II (Placebo)</title>
            <description>Patients receive placebo PO on day 1 and placebo PO QD on days 1-21 or 1-28. Patients then undergo prostatectomy.
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies
Placebo: Given PO</description>
          </group>
          <group group_id="O2">
            <title>Arm I (Cholecalciferol, Genistein)</title>
            <description>Patients receive cholecalciferol PO on day 1 and genistein PO QD on days 1-21 or 1-28. Patients then undergo prostatectomy.
Cholecalciferol: Given PO
Genistein: Given PO
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>PBMC CYP mRNA Expression of CYP24</title>
          <description>This is a measure of expression of CYP24 in comparing placebo to Cholecalciferol/genistein.</description>
          <population>Due to sample two participant in Arm I and 2 participants in Arm II were not analyzed for this Outcome.</population>
          <units>Ratio to Baseline</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.054" spread="3.997"/>
                    <measurement group_id="O2" value="2.202" spread="4.071"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PBMC CYP mRNA Expression of CYP27B1</title>
        <description>This is a measure of expression of CYP27B1 in comparing placebo to Cholecalciferol/genistein.</description>
        <time_frame>Up to Day 35</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm II (Placebo)</title>
            <description>Patients receive placebo PO on day 1 and placebo PO QD on days 1-21 or 1-28. Patients then undergo prostatectomy.
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies
Placebo: Given PO</description>
          </group>
          <group group_id="O2">
            <title>Arm I (Cholecalciferol, Genistein)</title>
            <description>Patients receive cholecalciferol PO on day 1 and genistein PO QD on days 1-21 or 1-28. Patients then undergo prostatectomy.
Cholecalciferol: Given PO
Genistein: Given PO
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>PBMC CYP mRNA Expression of CYP27B1</title>
          <description>This is a measure of expression of CYP27B1 in comparing placebo to Cholecalciferol/genistein.</description>
          <units>Ratio to Baseline</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.656" spread="2.628"/>
                    <measurement group_id="O2" value="2.389" spread="3.511"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total PSA in Serum</title>
        <description>This is a measure of the concentration of PSA in the blood serum at baseline and at the end of study.</description>
        <time_frame>at Baseline and up to Day 35</time_frame>
        <population>Due to sample one participant in Arm I was not analyzed for this Outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm II (Placebo)</title>
            <description>Patients receive placebo PO on day 1 and placebo PO QD on days 1-21 or 1-28. Patients then undergo prostatectomy.
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies
Placebo: Given PO</description>
          </group>
          <group group_id="O2">
            <title>Arm I (Cholecalciferol, Genistein)</title>
            <description>Patients receive cholecalciferol PO on day 1 and genistein PO QD on days 1-21 or 1-28. Patients then undergo prostatectomy.
Cholecalciferol: Given PO
Genistein: Given PO
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Total PSA in Serum</title>
          <description>This is a measure of the concentration of PSA in the blood serum at baseline and at the end of study.</description>
          <population>Due to sample one participant in Arm I was not analyzed for this Outcome.</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7" spread="7.3"/>
                    <measurement group_id="O2" value="6.3" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" spread="6.7"/>
                    <measurement group_id="O2" value="5.8" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Calcium Levels at Baseline and Pre-Surgery</title>
        <description>This is a measurement of calcium in the Blood serum at baseline and at the end of the study.</description>
        <time_frame>Baseline and Day 35</time_frame>
        <population>Due to sample one participant in Arm I was not analyzed for this Outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm II (Placebo)</title>
            <description>Patients receive placebo PO on day 1 and placebo PO QD on days 1-21 or 1-28. Patients then undergo prostatectomy.
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies
Placebo: Given PO</description>
          </group>
          <group group_id="O2">
            <title>Arm I (Cholecalciferol, Genistein)</title>
            <description>Patients receive cholecalciferol PO on day 1 and genistein PO QD on days 1-21 or 1-28. Patients then undergo prostatectomy.
Cholecalciferol: Given PO
Genistein: Given PO
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Calcium Levels at Baseline and Pre-Surgery</title>
          <description>This is a measurement of calcium in the Blood serum at baseline and at the end of the study.</description>
          <population>Due to sample one participant in Arm I was not analyzed for this Outcome.</population>
          <units>ng/mL (absolute change)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5" spread="0.4"/>
                    <measurement group_id="O2" value="11.3" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.8" spread="0.9"/>
                    <measurement group_id="O2" value="10.9" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total IGF-1 in Serum at Baseline and Pre-Surgery</title>
        <description>This is measuring the concentration of the Biomarker IGF-1 in blood serum at Baseline and at the end of the study.</description>
        <time_frame>Baseline and up to Day 35</time_frame>
        <population>Due to sample one participant in Arm I was not analyzed for this Outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm II (Placebo)</title>
            <description>Patients receive placebo PO on day 1 and placebo PO QD on days 1-21 or 1-28. Patients then undergo prostatectomy.
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies
Placebo: Given PO</description>
          </group>
          <group group_id="O2">
            <title>Arm I (Cholecalciferol, Genistein)</title>
            <description>Patients receive cholecalciferol PO on day 1 and genistein PO QD on days 1-21 or 1-28. Patients then undergo prostatectomy.
Cholecalciferol: Given PO
Genistein: Given PO
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Total IGF-1 in Serum at Baseline and Pre-Surgery</title>
          <description>This is measuring the concentration of the Biomarker IGF-1 in blood serum at Baseline and at the end of the study.</description>
          <population>Due to sample one participant in Arm I was not analyzed for this Outcome.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.2" spread="11.5"/>
                    <measurement group_id="O2" value="66.3" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.6" spread="17.9"/>
                    <measurement group_id="O2" value="74.6" spread="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total IGF-2 in Serum at Baseline and Pre-Surgery</title>
        <description>This is measuring the concentration of the Biomarker IGF-2 in blood serum at Baseline and at the end of the study</description>
        <time_frame>Baseline and Up to Day 35</time_frame>
        <population>Due to sample one participant in Arm 1 was not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm II (Placebo)</title>
            <description>Patients receive placebo PO on day 1 and placebo PO QD on days 1-21 or 1-28. Patients then undergo prostatectomy.
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies
Placebo: Given PO</description>
          </group>
          <group group_id="O2">
            <title>Arm I (Cholecalciferol, Genistein)</title>
            <description>Patients receive cholecalciferol PO on day 1 and genistein PO QD on days 1-21 or 1-28. Patients then undergo prostatectomy.
Cholecalciferol: Given PO
Genistein: Given PO
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Total IGF-2 in Serum at Baseline and Pre-Surgery</title>
          <description>This is measuring the concentration of the Biomarker IGF-2 in blood serum at Baseline and at the end of the study</description>
          <population>Due to sample one participant in Arm 1 was not analyzed.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="770.4" spread="333.4"/>
                    <measurement group_id="O2" value="805.9" spread="193.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-Surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="605.0" spread="175.4"/>
                    <measurement group_id="O2" value="858.8" spread="112.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total IGFBP-3 in Serum at Baseline and Pre-Surgery</title>
        <description>This is measuring the concentration of the Biomarker IGFBP-3 in blood serum at Baseline and at the end of the study.</description>
        <time_frame>Baseline and Up to Day 35</time_frame>
        <population>Due to sample one participant from Arm 1 was not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm II (Placebo)</title>
            <description>Patients receive placebo PO on day 1 and placebo PO QD on days 1-21 or 1-28. Patients then undergo prostatectomy.
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies
Placebo: Given PO</description>
          </group>
          <group group_id="O2">
            <title>Arm I (Cholecalciferol, Genistein)</title>
            <description>Patients receive cholecalciferol PO on day 1 and genistein PO QD on days 1-21 or 1-28. Patients then undergo prostatectomy.
Cholecalciferol: Given PO
Genistein: Given PO
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Total IGFBP-3 in Serum at Baseline and Pre-Surgery</title>
          <description>This is measuring the concentration of the Biomarker IGFBP-3 in blood serum at Baseline and at the end of the study.</description>
          <population>Due to sample one participant from Arm 1 was not analyzed.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1838.9" spread="887.3"/>
                    <measurement group_id="O2" value="2004.5" spread="309.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1667.5" spread="788.9"/>
                    <measurement group_id="O2" value="1843.4" spread="443.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total PTH in Serum at Baseline and Pre-Surgery</title>
        <description>This is measuring the concentration of the Biomarker PTH in blood serum at Baseline and at the end of the study</description>
        <time_frame>Baseline and Up to Day 35</time_frame>
        <population>Due to sample one participant in Arm I was not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm II (Placebo)</title>
            <description>Patients receive placebo PO on day 1 and placebo PO QD on days 1-21 or 1-28. Patients then undergo prostatectomy.
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies
Placebo: Given PO</description>
          </group>
          <group group_id="O2">
            <title>Arm I (Cholecalciferol, Genistein)</title>
            <description>Patients receive cholecalciferol PO on day 1 and genistein PO QD on days 1-21 or 1-28. Patients then undergo prostatectomy.
Cholecalciferol: Given PO
Genistein: Given PO
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Total PTH in Serum at Baseline and Pre-Surgery</title>
          <description>This is measuring the concentration of the Biomarker PTH in blood serum at Baseline and at the end of the study</description>
          <population>Due to sample one participant in Arm I was not analyzed.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143.4" spread="26.5"/>
                    <measurement group_id="O2" value="144.8" spread="37.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-Surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151.1" spread="25.8"/>
                    <measurement group_id="O2" value="136.5" spread="72.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunohistochemistry Measurements in Benign Prostate Tissue (BPT)</title>
        <description>The Immunohistochemistry measurement for: AR (Nucleus), VDR (Cytoplasm), p21 (Nucleus), PGE2 (Cytoplasm), TUNEL Pos (Nucleus), Caspase 3 (Cytoplasm), PSMA (Cytoplasm), IGF-1 and IGF-2 (Cytoplasm), Akt (Nucleus and Cytoplasm), and pAkt (nucleus and Cytoplasm)
This is to serve as normalized control data to determine expression of protein.
The normalized optical densities were measured as optical density per unit area by densitometric scanning using Vectra imaging system (Perkin Elmer).
This Optical Density is based on fluorescence.</description>
        <time_frame>Up to Day 35</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm II (Placebo)</title>
            <description>Patients receive placebo PO on day 1 and placebo PO QD on days 1-21 or 1-28. Patients then undergo prostatectomy.
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies
Placebo: Given PO</description>
          </group>
          <group group_id="O2">
            <title>Arm I (Cholecalciferol, Genistein)</title>
            <description>Patients receive cholecalciferol PO on day 1 and genistein PO QD on days 1-21 or 1-28. Patients then undergo prostatectomy.
Cholecalciferol: Given PO
Genistein: Given PO
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Immunohistochemistry Measurements in Benign Prostate Tissue (BPT)</title>
          <description>The Immunohistochemistry measurement for: AR (Nucleus), VDR (Cytoplasm), p21 (Nucleus), PGE2 (Cytoplasm), TUNEL Pos (Nucleus), Caspase 3 (Cytoplasm), PSMA (Cytoplasm), IGF-1 and IGF-2 (Cytoplasm), Akt (Nucleus and Cytoplasm), and pAkt (nucleus and Cytoplasm)
This is to serve as normalized control data to determine expression of protein.
The normalized optical densities were measured as optical density per unit area by densitometric scanning using Vectra imaging system (Perkin Elmer).
This Optical Density is based on fluorescence.</description>
          <units>Normalized Optical Density</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AR (Nucleus)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.362" spread="0.294"/>
                    <measurement group_id="O2" value="0.414" spread="1.301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VDR (Cytoplasm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.451" spread="0.410"/>
                    <measurement group_id="O2" value="0.515" spread="1.179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p21 (Nucleus)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.085" spread="1.070"/>
                    <measurement group_id="O2" value="0.097" spread="0.900"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PGE2 (Cytoplasm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.161" spread="1.023"/>
                    <measurement group_id="O2" value="0.184" spread="0.934"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TUNEL Pos (Nucleus)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.168" spread="0.842"/>
                    <measurement group_id="O2" value="0.192" spread="1.122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caspase 3 (Cytoplasm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.308" spread="0.659"/>
                    <measurement group_id="O2" value="0.352" spread="1.178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PSMA (Cytoplasm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.025" spread="1.231"/>
                    <measurement group_id="O2" value="-0.029" spread="0.630"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IGF-1 (Cytoplasm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.295" spread="0.607"/>
                    <measurement group_id="O2" value="0.337" spread="1.220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IGF-2 (Cytoplasm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.335" spread="0.763"/>
                    <measurement group_id="O2" value="0.383" spread="1.081"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Akt (Nucleus)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.316" spread="0.618"/>
                    <measurement group_id="O2" value="0.361" spread="1.198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pAkt (Nucleus)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.114" spread="0.920"/>
                    <measurement group_id="O2" value="0.131" spread="1.068"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Akt (Cytoplasm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.249" spread="0.766"/>
                    <measurement group_id="O2" value="0.284" spread="1.142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pAkt (Cytoplasm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.053" spread="1.004"/>
                    <measurement group_id="O2" value="0.061" spread="0.991"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunohistochemistry Measurements in Prostate Cancer Tissue (PCA)</title>
        <description>The Immunohistochemistry measurement for: AR (Nucleus), VDR (Cytoplasm), p21 (Nucleus), PGE2 (Cytoplasm), TUNEL Pos (Nucleus), Caspase 3 (Cytoplasm), PSMA (Cytoplasm), IGF-1 and IGF-2 (Cytoplasm), Akt (Nucleus and Cytoplasm), and pAkt (nucleus and Cytoplasm)
This is to serve as normalized case data to determine expression of protein.
The normalized optical densities were measured as optical density per unit area by densitometric scanning using Vectra imaging system (Perkin Elmer).
This Optical Density is based on fluorescence.</description>
        <time_frame>Up to day Day 35</time_frame>
        <population>Due to sample in Arm II one participants data was not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm II (Placebo)</title>
            <description>Patients receive placebo PO on day 1 and placebo PO QD on days 1-21 or 1-28. Patients then undergo prostatectomy.
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies
Placebo: Given PO</description>
          </group>
          <group group_id="O2">
            <title>Arm I (Cholecalciferol, Genistein)</title>
            <description>Patients receive cholecalciferol PO on day 1 and genistein PO QD on days 1-21 or 1-28. Patients then undergo prostatectomy.
Cholecalciferol: Given PO
Genistein: Given PO
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Immunohistochemistry Measurements in Prostate Cancer Tissue (PCA)</title>
          <description>The Immunohistochemistry measurement for: AR (Nucleus), VDR (Cytoplasm), p21 (Nucleus), PGE2 (Cytoplasm), TUNEL Pos (Nucleus), Caspase 3 (Cytoplasm), PSMA (Cytoplasm), IGF-1 and IGF-2 (Cytoplasm), Akt (Nucleus and Cytoplasm), and pAkt (nucleus and Cytoplasm)
This is to serve as normalized case data to determine expression of protein.
The normalized optical densities were measured as optical density per unit area by densitometric scanning using Vectra imaging system (Perkin Elmer).
This Optical Density is based on fluorescence.</description>
          <population>Due to sample in Arm II one participants data was not analyzed.</population>
          <units>Normalized Optical Density</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AR (Nucleus)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.563" spread="0.481"/>
                    <measurement group_id="O2" value="0.563" spread="1.015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VDR (Cytoplasm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.281" spread="0.657"/>
                    <measurement group_id="O2" value="0.281" spread="1.177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p21 (Nucleus)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.185" spread="0.489"/>
                    <measurement group_id="O2" value="0.185" spread="1.296"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PGE2 (Cytoplasm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.135" spread="0.969"/>
                    <measurement group_id="O2" value="0.135" spread="1.009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TUNEL Pos (Nucleus)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.363" spread="0.664"/>
                    <measurement group_id="O2" value="0.363" spread="1.119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caspase 3 (Cytoplasm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.103" spread="0.742"/>
                    <measurement group_id="O2" value="0.103" spread="1.194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PSMA (Cytoplasm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.210" spread="0.966"/>
                    <measurement group_id="O2" value="0.210" spread="0.982"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IGF-1 (Cytoplasm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.155" spread="1.027"/>
                    <measurement group_id="O2" value="-0.155" spread="0.943"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IGF-2 (Cytoplasm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.443" spread="1.102"/>
                    <measurement group_id="O2" value="-0.443" spread="0.572"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Akt (Nucleus)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.309" spread="0.903"/>
                    <measurement group_id="O2" value="0.309" spread="0.981"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pAkt (Nucleus)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.291" spread="0.325"/>
                    <measurement group_id="O2" value="0.291" spread="1.302"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Akt (Cytoplasm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.379" spread="0.785"/>
                    <measurement group_id="O2" value="0.379" spread="1.024"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pAkt (Cytoplasm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.365" spread="0.377"/>
                    <measurement group_id="O2" value="0.365" spread="1.244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants With CYP24 and CYP27B1 SNPs (DNA From Paxgene)</title>
        <time_frame>up to Day 35</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm II (Placebo)</title>
            <description>Patients receive placebo PO on day 1 and placebo PO QD on days 1-21 or 1-28. Patients then undergo prostatectomy.
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies
Placebo: Given PO</description>
          </group>
          <group group_id="O2">
            <title>Arm I (Cholecalciferol, Genistein)</title>
            <description>Patients receive cholecalciferol PO on day 1 and genistein PO QD on days 1-21 or 1-28. Patients then undergo prostatectomy.
Cholecalciferol: Given PO
Genistein: Given PO
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With CYP24 and CYP27B1 SNPs (DNA From Paxgene)</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>rs2209314- T/C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.5"/>
                    <measurement group_id="O2" value="42.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rs2209314- T/T</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.5"/>
                    <measurement group_id="O2" value="57.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rs2248359- C/C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.5"/>
                    <measurement group_id="O2" value="42.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rs2248359- C/T</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.5"/>
                    <measurement group_id="O2" value="57.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rs2248359- T/T</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rs2296241- A/A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.5"/>
                    <measurement group_id="O2" value="14.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rs2296241- A/G</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.5"/>
                    <measurement group_id="O2" value="71.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rs2296241- G/G</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="14.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rs2762939- C/G</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.5"/>
                    <measurement group_id="O2" value="28.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rs2762939- G/G</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.5"/>
                    <measurement group_id="O2" value="71.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rs927650- C/C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="71.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rs927650- C/T</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="14.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rs927650- T/T</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="14.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rs703842- A/A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="14.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rs703842- A/G</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.5"/>
                    <measurement group_id="O2" value="71.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rs703842- G/G</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5"/>
                    <measurement group_id="O2" value="14.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Arm II (Placebo)</title>
          <description>Patients receive placebo PO on day 1 and placebo PO QD on days 1-21 or 1-28. Patients then undergo prostatectomy.
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies
Placebo: Given PO</description>
        </group>
        <group group_id="E2">
          <title>Arm I (Cholecalciferol, Genistein)</title>
          <description>Patients receive cholecalciferol PO on day 1 and genistein PO QD on days 1-21 or 1-28. Patients then undergo prostatectomy.
Cholecalciferol: Given PO
Genistein: Given PO
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>hyperthyriodism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>blood bilirubin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>increased serum chloride</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>platelet count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>hyperglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>hypophosphatemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>sinus pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>allergic rhinitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>calcified lung nodule-right ct scan</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Howard H. Bailey</name_or_title>
      <organization>University of Wisconsin</organization>
      <phone>608-263-8624</phone>
      <email>hhbailey@wisc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

